Hemoglobin specific volume width might promote the prevalence and poor long-term prognosis of American cardiovascular disease adult patients: the NHANES 1999-2020

Lin Zhang; Jun Chang; Kaiyue Wang; Ying Zhou; Liming Wang; Lele Zhang; Xuemei Zhang; Zhifei Fu; Lifeng Han; Xiumei Gao

doi:10.1101/2023.09.07.23295178

Abstract

Background Cardiovascular disease (CVD) patients are always accompanied by erythrocyte dysfunction. However, current erythrocyte-related indicators can’t explain the prevalence and long-term prognosis of CVD. Therefore, hemoglobin specific volume width (HSW) was first created to explain this phenomenon.

Methods HSW’s quartiles were determined with Q1 [1.88,3.64] cL/g, Q2 (3.64,3.85] cL/g, Q3 (3.85,4.11] cL/g, and Q4 (4.11,11.74] cL/g. Among the 57,894 participants derived from National Health and Nutrition Examination Survey (NMAHES), 5,623 CVD patients had a whole following time (median 79 months). Logistic regression, Cox regression, Kaplan–Meier curves, and restricted cubic spline were utilized for analysis.

Results Among the non-CVD (n=51,243) and CVD (n=6,651) individuals, the percentages of CVD in quartiles of HSW (Q1, Q2, Q3, and Q4) were 4.95%, 7.11%, 10.51%, and 16.14% (P < 0.0001). Adjusted odds ratio (OR) was still significant, 1.46 (95% CI 1.33, 1.60). Processing Q1 as reference, the adjusted ORs for Q3 and Q4 were 1.19(95% CI 1.05,1.35) and 1.54 (95% CI 1.36,1.73). Females had a higher risk (OR 1.49, 95% CI 1.32, 1.68) of CVD than males with increasing HSW. Diabetes mellitus (DM) patients had the highest risk of CVD (OR 1.54, 95% CI 1.30,1.84) than preDM or healthy individuals. Among dead (n=2,517) and alive CVD (n=3,106) patients, the adjusted HSW hazard ratio (HR) was 1.70 (95% CI 1.48,1.95). An inverse L-curve with an inflexion point of 3.96 was observed between HR and CVD. CVD patients with HSW > 3.96 had a poor prognosis than HSW <= 3.96.

Conclusions HSW is a novel risk for CVD prevalence and long-term prognosis. Females and DM patients have a higher risk of CVD when HSW increases.

Competing Interest Statement

The authors have declared no competing interest.

Funding Statement

Our research was supported by the Tianjin Committee of Science and Technology of China (22ZYJDSS00040) and the Science and Technology Project of Haihe Laboratory of Modern Chinese Medicine (22HHZYSS00007).

Author Declarations

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Yes

I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.

Yes